Evidence map›Paper›PMID 35844232›Full record

ArticleFrontiers in neuroscience2022

The Effect of Neuroepo on Cognition in Parkinson's Disease Patients Is Mediated by Electroencephalogram Source Activity.

Maria L Bringas Vega, Ivonne Pedroso Ibáñez, Fuleah A Razzaq, Min Zhang, Lilia Morales Chacón, Peng Ren, Lidice Galan Garcia, Peng Gan, Trinidad Virues Alba, Carlos Lopez Naranjo and 3 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in neuroscience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04110678 (Nasal Administration of the NeuroEPO in Parkinson Disease), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04110678 phase1 / phase2completednot on this map

Nasal Administration of the NeuroEPO in Parkinson Disease: Short-term Tolerance Physician Lead Trial

TypeinterventionalSponsorInternational Center for Neurological Restoration, CubaRan2015 to 2017Enrolled26ConditionsParkinson DiseaseArmsNeuroEPO
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Nose-to-brain drug delivery: from bench to bedside.Translational neurodegeneration · 2025
    Review
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 4 countries.

Maria L Bringas VegaMinistry of Education (MOE) Key Lab for Neuroinformation, The Clinical Hospital of Chengdu Brain Science Institute, University of Electronic Science and Technology of China, Chengdu, China.
Ivonne Pedroso IbáñezInternational Center of Neurological Restoration (CIREN), La Habana, Cuba.
Fuleah A RazzaqMinistry of Education (MOE) Key Lab for Neuroinformation, The Clinical Hospital of Chengdu Brain Science Institute, University of Electronic Science and Technology of China, Chengdu, China.
Min ZhangMinistry of Education (MOE) Key Lab for Neuroinformation, The Clinical Hospital of Chengdu Brain Science Institute, University of Electronic Science and Technology of China, Chengdu, China.
Lilia Morales ChacónInternational Center of Neurological Restoration (CIREN), La Habana, Cuba.
Peng RenMinistry of Education (MOE) Key Lab for Neuroinformation, The Clinical Hospital of Chengdu Brain Science Institute, University of Electronic Science and Technology of China, Chengdu, China.
Lidice Galan GarciaCuban Neuroscience Center (CNEURO), La Habana, Cuba.
Peng GanMinistry of Education (MOE) Key Lab for Neuroinformation, The Clinical Hospital of Chengdu Brain Science Institute, University of Electronic Science and Technology of China, Chengdu, China.
Trinidad Virues AlbaCuban Neuroscience Center (CNEURO), La Habana, Cuba.
Carlos Lopez NaranjoMinistry of Education (MOE) Key Lab for Neuroinformation, The Clinical Hospital of Chengdu Brain Science Institute, University of Electronic Science and Technology of China, Chengdu, China.
Marjan JahanshahiMinistry of Education (MOE) Key Lab for Neuroinformation, The Clinical Hospital of Chengdu Brain Science Institute, University of Electronic Science and Technology of China, Chengdu, China.
Jorge Bosch-BayardMinistry of Education (MOE) Key Lab for Neuroinformation, The Clinical Hospital of Chengdu Brain Science Institute, University of Electronic Science and Technology of China, Chengdu, China.
Pedro A Valdes-SosaMinistry of Education (MOE) Key Lab for Neuroinformation, The Clinical Hospital of Chengdu Brain Science Institute, University of Electronic Science and Technology of China, Chengdu, China.
University of Electronic Science and Technology of China · CNCuban Neuroscience Center · CUInternational Center of Neurologic Restoration · CUMontreal Neurological Institute and Hospital · CANational Hospital for Neurology and Neurosurgery · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We report on the quantitative electroencephalogram (qEEG) and cognitive effects of Neuroepo in Parkinson's disease (PD) from a double-blind safety trial (https://clinicaltrials.gov/, number NCT04110678). Neuroepo is a new erythropoietin (EPO) formulation with a low sialic acid content with satisfactory results in animal models and tolerance in healthy participants and PD patients. In this study, 26 PD patients were assigned randomly to Neuroepo (

Indexed as

Canonical Correlation Analysis (CCA)EEGNeuroepoParkinson’s diseasesource analysiswhitening

Identifiers

PMID35844232
PMCPMC9280298
OpenAlexW4283751343

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.